Morgan Stanley reiterated coverage on Evofem Biosciences with a new price target

8/12/21 7:53:05 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Morgan Stanley reiterated coverage of Evofem Biosciences with a rating of Equal-Weight and set a new price target of $1.00 from $3.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EVFM

Date	Price Target	Rating	Analyst
3/4/2022	$0.50 → $0.53	Underweight	Morgan Stanley
11/16/2021	$2.50 → $2.00	Buy	HC Wainwright & Co.
10/21/2021	$4.00 → $2.50	Buy	HC Wainwright & Co.
10/14/2021	$0.80	Equal-Weight → Underweight	Morgan Stanley
8/12/2021	$3.00 → $1.00	Equal-Weight	Morgan Stanley